Why Did Greenwich LifeSciences (GLSI) Soar 13.56%?

Greenwich LifeSciences (GLSI) has seen a remarkable surge in its stock price, rising 13.56% in pre-market trading on April 8, 2025. This significant increase comes on the heels of several key developments within the company.

One of the most notable events is the substantial investment made by CEO and CFO Snehal Patel, who purchased 5,500 shares of the company’s stock, valued at $48,015. This insider activity has bolstered investor confidence in the company’s future prospects.

Additionally, Greenwich LifeSciences has reported encouraging progress in its Phase III FLAMINGO-01 clinical trial. The trial, which is evaluating the immunotherapy GLSI-100 for preventing breast cancer recurrences, has shown positive immune responses in both HLA-A*02 and non-HLA-A*02 patient groups. This has led to an expansion of the non-HLA-A*02 arm, potentially transforming it into a second Phase III trial. The company has also filed new patent claims that could double the eligible patient population, further enhancing the market potential for GLSI-100.

Despite these positive developments, the company has delayed its yearly report filing due to a significant increase in R&D expenses, which has impacted its financial statements. This has led analysts to focus on the trial’s promising data while also considering the financial implications of increased R&D spending. Overall, the recent developments have positioned Greenwich LifeSciences for potential growth, with analysts maintaining a strong buy sentiment for the stock.